A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

NCT02013765 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Trial was terminated prematurely because of recruitment difficulties.

Conditions

Urinary Tract Cancer

Interventions

DRUG: trastuzumab

Sponsor

Hoffmann-La Roche